Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | MGLL | Q99685 | 1/20 | 0.60 |
| ▸ | F2 | P00734 | 3/20 | 0.59 |
| ▸ | F10 | P00742 | 3/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5439749 | 0.93 | SMN1; SMN2 (0.57) | SMN1; SMN2HTTMGLLF2F10 | |
| SCHEMBL1037979 | 0.89 | SMN1; SMN2 (0.64) | SMN1; SMN2HTTMGLLF2F10 | |
| SCHEMBL1038642 | 0.89 | MGLL (0.70) | SMN1; SMN2HTTMGLLF2F10 | |
| SCHEMBL1037469 | 0.85 | SMN1; SMN2 (0.69) | SMN1; SMN2HTTMGLLF2F10 | |
| SCHEMBL5427213 | 0.84 | SMN1; SMN2 (0.67) | SMN1; SMN2HTTMGLLF2F10 | |
| SCHEMBL1037100 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2HTTMGLLF2F10 | |
| Hydrochloric Acid SCHEMBL1081045 | 0.84 | SMN1; SMN2 (0.67) | SMN1; SMN2HTTMGLLF2F10 | |
| SCHEMBL1037695 | 0.83 | SMN1; SMN2 (0.67) | SMN1; SMN2HTTMGLLF2F10 | |
| SCHEMBL1036943 | 0.82 | MGLL (0.62) | SMN1; SMN2HTTMGLLF2F10 | |
| SCHEMBL1038179 | 0.80 | SMN1; SMN2 (0.59) | SMN1; SMN2HTTMGLLF2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948616-B1 | 2-(BENZIMIDAZOL-1-YL)-ACETAMIDE BIARYL DERIVATIVES AND THEIR USE AS INHIBITORS OF THE TRPV1 RECEPTOR | ORGANON NV (NL) | 2011-01-26 | — | — | EP | claimed |
| US-7482469-B2 | 2-(benzimidazol-1-yl)-acetamide bisaryl derivatives | N.V. ORGANON (NL) | 2009-01-27 | — | — | US | claimed |
| EP-1948616-B1 | 2-(BENZIMIDAZOL-1-YL)-ACETAMIDE BIARYL DERIVATIVES AND THEIR USE AS INHIBITORS OF THE TRPV1 RECEPTOR | ORGANON NV (NL) | 2011-01-26 | — | — | EP | disclosed |
| US-7482469-B2 | 2-(benzimidazol-1-yl)-acetamide bisaryl derivatives | N.V. ORGANON (NL) | 2009-01-27 | — | — | US | disclosed |
| US-20070112034-A1 | 2-(benzimidazol-1-yl)-acetamide bisaryl derivatives | AKZO NOBEL N.V. (NL) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112034-A1 | 2-(benzimidazol-1-yl)-acetamide bisaryl derivatives | TRPV1, TRPV3, TRPV2 | SMN1; SMN2 3054/4885HTT 2439/4885MGLL 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.